YU-SHAN HUANGSZU-MIN HSIEHFENG-CHIAO TSAICHIEN-CHIH TUNGHUNG-CHIH YANGSUI-YUAN CHANGJANN-TAY WANGCHUN-JEN LIUTUNG-HUNG SUJIA-HORNG KAO2024-07-152024-07-152024-06-2009296646https://scholars.lib.ntu.edu.tw/handle/123456789/719767Longitudinal analysis of antibody responses following three-dose COVID-19 vaccination in patients with chronic liver disease (CLD) has been limited. From August 2021 to February 2023, sequential anti-SARS-CoV-2 spike IgG titers were determined in 45 patients with CLD who received two or three doses of COVID-19 vaccine. The geometric mean of anti-spike IgG at four weeks after the second and third doses were 1313.16 BAU/mL and 3042.29 BAU/mL, respectively, and it decreased significantly from four to 24 weeks after the second (1313.16 vs. 198.42 BAU/mL, p = 0.002) and the third (3042.29 vs. 636.71 BAU/mL, p < 0.001) dose. The anti-spike IgG titers in participants receiving prime-boost homologous mRNA vaccines (BNT162b2 or mRNA-1273) were comparable between participants with and those without significant liver fibrosis at each follow-up time point. This study demonstrated a notable decrease in anti-spike IgG after completion of the vaccination schedule in patients with CLD, highlighting the importance of additional booster doses.entrueAntibodiesCOVID-19Chronic liver diseaseLiver fibrosisVaccine[SDGs]SDG3journal article10.1016/j.jfma.2024.06.015389067312-s2.0-85196615455